Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework
- 1 April 2017
- journal article
- research article
- Published by Elsevier in Neurobiology of Aging
- Vol. 52, 153-166
Abstract
No abstract availableKeywords
Funding Information
- IXICO
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (IZ32Z0_157953)
This publication has 110 references indexed in Scilit:
- MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy studyBMJ Open, 2013
- Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performanceNeurobiology of Aging, 2012
- Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the LiteratureJournal of Neuropathology & Experimental Neurology, 2012
- Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective studyThe Lancet Neurology, 2011
- Free and Cued Selective Reminding Identifies Very Mild Dementia in Primary CareAlzheimer Disease & Associated Disorders, 2010
- Brain substrates of learning and retention in mild cognitive impairment diagnosis and progression to Alzheimer's diseaseNeuropsychologia, 2010
- The Episodic Memory System: Neurocircuitry and DisordersNeuropsychopharmacology, 2009
- 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairmentBrain, 2008
- The hippocampus is required for short‐term topographical memory in humansHippocampus, 2006
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991